Meningococcemia overview

Revision as of 14:05, 26 November 2014 by Ammu Susheela (talk | contribs)
Jump to navigation Jump to search

Meningococcemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Meningococcemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Treatment

Medical Therapy

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Meningococcemia overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Meningococcemia overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Meningococcemia overview

CDC on Meningococcemia overview

Meningococcemia overview in the news

Blogs on Meningococcemia overview

Directions to Hospitals Treating Meningococcemia

Risk calculators and risk factors for Meningococcemia overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Overview

Meningococcemia is the presence of Neisseria meningitidis (also known as meningococcus), a severe bacterical infection, in the blood stream. It is demonstrated by blood culture. The disease is hard to identify as it can appear in several different forms, depending on which part of the body the bacteria invade. Neisseria meningitides is a gram-negative diplococcus. The bacteria is known to cause meningitis, septicaemia, pneumonia, and even rarely urethritis. Early recognition and treatment of anyone exposed to meningococcus is extremely important to prevent serious illness or death.

Historical Perspective

The historical reports indicate that meningococci was first reported in 1805. SInce then for more than 2 hundred years, meningococcus have been causing a high degree of morbidity and mortality. It usually appear as sporadic but reports of outbreak have been reported from different parts of the world especially Sub Saharan African belt. Outbreak usually happens in close communities like schools, colleges and prisons.

Meningococcemia Classification

13 serotypes of meningococci have been isolated based on their polysacchride capsule out of which five of them causes clinically severe diseases. They are also classified according to outer me

Pathophysiology

Meningococcal infection is caused by Neisseria meningitidis and they spread through respiratory and throat secretions. Once it get absorbed by endocytosis into the body, it get seeded in skin , meninges and other organs and cause a variety of clinical manifestation from meningitis to septicemic shock. The meningococcal lipopolysachride is an important factor in the infection and host factors like Toll like receptor (TLR) and inflammatory cytokines play an important role in the pathogenesis of the disease.

Causes

Meningococcemia is caused by a bacteria called Neisseria meningitidis. The bacteria frequently lives in a person'supper respiratory tract without causing visible signs of illness. The bacteria can be spread from person to person through respiratory droplets -- for example, you may become infected if you are around someone with the condition when they sneeze or cough. Family members and those closely exposed to someone with the condition are at increased risk. The infection occurs more frequently in winter and early spring.

Differential Diagnosis

The rash component of meningococcemia must be differentiated from other illnesses causing skin rash, such as chickenpox, herpes zoster, erythema multiforme, among others.

Epidemiology and Demographics

Meningococcus occurs through out the year, however the incidence is highest in late winter and early spring. It is the second most common community acquired bacterial infections. The highest incidence worldwide is in a place called sub Saharan Africa called meningitis belt. Children are mostly affected by this disease.

Risk Factors

Risk factors of meningococcemia include age group of infants or old age, closed communities, seasons of winter and early spring, complement deficiency, asplenia and travel to endemic regions especially sub-Saharan African meningitis belt.

Screening

Routine screening is not recommended for meningococcemia.

Natural history, Complications and Prognosis

[Nesseria meningitidis]] bacteria can cause meningitis to fatal septicemia. The symptoms of meningitis appear within 3-7 days of exposure and presents with fever and signs of bacterial meningitis. If it causes septicemia, it can be very fatal where the patient dies in few hours. In non fatal conditions they develop disabilities like arthritis, gangrene, Disseminated intravascular coagulopathy and cutaneous vasculitis. The outcome is uncertain in septicemic patients but prognosis is good in non septicemic patients with early intervention and treatment.

History and symptoms

Every child with purpuric rash and high fever should be treated as meningococcemia until proven otherwise. The history suggest patient with high fever, rash, headache, myalgia and stiff neck.

Physical Examination

Physical examination may shows fever, hypotension, petechial rash, conjuctival congestion, nuchal rigidity, seizures, edema, hepatospleenomegaly, dyspnea and rales.

Laboratory findings

Meningococci is usually identified from blood or CSF analysis. Aspiration or skin biopsy of the rash yield meningococci. CSF analysis usually shows increased protein, low glucose and increased number of neutrophils.

Medical Therapy

Meningococcemia is a medical emergency. Breathing support, fluid resucitation, antibiotics like cephalosporin and wound care are the major aspects of treatment.

Primary Prevention

Primary prevention of meningococcemia includes vaccination and chemo prophylaxis. There are mainly 2 different types of vaccine namely polysacchride and conjugate vaccine. Chemoprophylaxis is mainly with rifampin, ceftriaxone, ciprofloxicin and azithromycin.

Cost-effectiveness of Therapy

Cost effective analysis study has indicated that a 2-dose series at ages 11 years and 16 years has a similar cost-effectiveness compared with moving the single dose to age 15 years or maintaining the single dose at 11 years.

Future or Investigational Therapies

Future investigational therapies are showing promising results where 2 new vaccines were being developed against serogroup B and 3 new types of antigen have been found to be useful in making vaccines more potent.

References


Template:WikiDoc Sources